Delivery Order SPE2DB20D2014-SPE2DB26FA13Z
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Jardiance 10 mg tablets (90-count units) with a contract ceiling value of $23,977.17. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded procurement. The order is scheduled for completion by August 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Jardiance 25 mg tablets (90-count) with a ceiling value of $51,243.85. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is scheduled for completion by August 21, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Jardiance 25 mg tablets (30-count packaging) under a firm fixed-price contract valued at $2,260.38. This non-set-aside competitive award is classified as a delivery order, with an ultimate completion date of July 29, 2025. The pharmaceutical distributor will perform this work at its corporate headquarters location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Jardiance 25 mg tablets (90-count units) with a ceiling value of $1,861.15. This firm fixed-price delivery order, which is due for completion by September 4, 2025, represents a continuation of AmerisourceBergen's role as a pharmaceutical supplier to the federal government. The award carries no set-aside designation, indicating it was competitively awarded....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 15, 2025, for the supply of Jardiance 10 mg tablets (90-count units) with a ceiling value of $5,543.64. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion by October 16, 2025, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Jardiance 25 mg tablets (90-count packages) with a ceiling value of $6,717.68. This is a firm fixed-price delivery order with no set-aside designation, completed competitively through open procurement. The order is scheduled for ultimate completion on August 15, 2025, and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Jardiance 25 mg tablets in a 90-count package. This firm fixed-price delivery order, valued at $106,293.56, is scheduled for completion by August 8, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Jardiance 10 mg tablets (90-count) with a ceiling value of $9,728.31. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is due for completion by September 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Jardiance 10 mg tablets (90-count) with a ceiling value of $6,657.98. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order is set for completion by September 5, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Jardiance 25 mg tablets (90-count units) under a firm fixed-price contract type. The order, valued at $4,520.58, is scheduled for completion by July 21, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designations, reflecting AmerisourceBergen's established capability to...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB26FA13ZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Jardiance 25 mg tablets (90-count units) with a contract ceiling value of $32,802.10. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion on October 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor serving federal healthcare systems, AmerisourceBergen is well-positioned to fulfill this diabetes medication requirement for military and veteran healthcare supply needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999 and extending through December 2026. This comprehensive prime vendor agreement enables the contractor to supply a broad range of pharmaceutical products and medical supplies supporting military healthcare programs globally. The ongoing DLA Pharmaceutical Prime Vendor Global Program Generation V initiative is expected to include multiple regional awards with several contractors, demonstrating the agency's strategy to maintain diverse pharmaceutical supply sources across the defense healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $32.8k | 10/20/25 |